Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency during Surgery or Childbirth

Bruce A. Schwartz, Cristina Solomon, Sigurd Knaub, Craig M. Kessler

Blood (2021) 138 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2021-152594

Published: 2021

Journal Articles

Efficacy and Safety of Human Fibrinogen Concentrate for the Treatment of Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials

Claudia Djambas Khayat, MD BSc, Irina Kruzhkova, Cristina Solomon, Bruce A. Schwartz, PhD, Flora Peyvandi

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141280

Published: 2020

Journal Articles

Fiirst-2: Prospective, Randomized Study Comparing Administration of Clotting Factor Concentrates with Standard Massive Hemorrhage Protocol in Severely Bleeding Trauma Patients

Luis Da Luz, MD, Jeannie L Callum, MD, Andrew Beckett, MD, Henry T Peng, PhD, Paul Engels, MD, Neil Parry, MD, Homer Tien, MD, Avery Nathens, MDMPH PhD, Bruce A. Schwartz, PhD, Keyvan Karkouti, MD MSc, FRCPC

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-141329

Published: 2020

Journal Articles

Real-World Experience with a New Human Fibrinogen Concentrate (Fibryga®) in France for the Treatment of Bleeding Episodes and Surgical Prophylaxis

François Stephan, Laure Gutermann, Martine Pennetier, Stephanie Bourget, Sarah Djabarouti, Johanna Berdugo, Yann Fardini, Pierre Clerson, Bruce A. Schwartz, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141303

Published: 2020

Journal Articles

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Robert F. Sidonio, Jr., MD MSc, Bruce A. Schwartz, PhD

Blood (2019) 134 (Supplement_1): 4931.

https://doi.org/10.1182/blood-2019-128339

Published: 2019

Journal Articles

Safety and Efficacy of Fibrinogen Concentrate in Congenital Fibrinogen Deficiency: A Post-Marketing Observational Study

Bruce A. Schwartz, PhD, Flora Peyvandi, MD PhD, Cristina Solomon, Sigurd Knaub, Balazs Toth

Blood (2019) 134 (Supplement_1): 4971.

https://doi.org/10.1182/blood-2019-129891

Published: 2019

Journal Articles

Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency

Flora Peyvandi, MD PhD, Bruce A. Schwartz, Sigurd Knaub

Blood (2018) 132 (Supplement 1): 2501.

https://doi.org/10.1182/blood-2018-99-116572

Published: 2018

Journal Articles

Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency — a Phase 3 Study

Flora Peyvandi, MD PhD, Bruce A. Schwartz, Sigurd Knaub

Blood (2018) 132 (Supplement 1): 2502.

https://doi.org/10.1182/blood-2018-99-116440

Published: 2018

Journal Articles

Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency

Bruce A. Schwartz, PhD, Cecil Ross, MD, Bella Madan, MD, Toshko Jelev Lissitchkov, MD, Mehran Karimi, MD, Sigurd Knaub, Flora Peyvandi, MD PhD

Blood (2016) 128 (22): 1404.

https://doi.org/10.1182/blood.V128.22.1404.1404

Published: 2016

Journal Articles

Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis

Cecil Ross, MD, Savita Rangarajan, Mehran Karimi, MD, Bruce A. Schwartz, PhD, Sigurd Knaub, PhD, Flora Peyvandi, MD PhD

Blood (2015) 126 (23): 4680.

https://doi.org/10.1182/blood.V126.23.4680.4680

Published: 2015

Journal Articles

Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency

Bruce A. Schwartz, PhD, Savita Rangarajan, MBBS, FRCP, FRCPath, Flora Peyvandi, Mehran Karimi, MD, Sigurd Knaub, PhD

Blood (2014) 124 (21): 2817.

https://doi.org/10.1182/blood.V124.21.2817.2817

Published: 2014

Journal Articles

Surgery in Von Willebrand Disease (VWD) Is Facilitated By a Novel 1:1 Plasma Derived Human Factor VWF/VIII Concentrate

Alok Srivastava, MD, Margit Serban, Prof. Dr., Sylvia Werner, Bruce A. Schwartz, PhD, Sigurd Knaub, PhD, Craig M. Kessler, MD

Blood (2014) 124 (21): 1504.

https://doi.org/10.1182/blood.V124.21.1504.1504

Published: 2014

Journal Articles

Role of Von Willebrand Factor Triplet Bands in Glycoprotein Ib-Dependent Platelet Adhesion Under Flow Conditions

Bruce A. Schwartz, PhD, Christoph Kannicht, PhD, Birte Fuchs, PhD, Mario Kröning, Barbera Solecka, PhD

Blood (2012) 120 (21): 3356.

https://doi.org/10.1182/blood.V120.21.3356.3356

Published: 2012

Journal Articles

Treatment of Congenital Fibrinogen Deficiency; Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate

Bruce A. Schwartz, PhD, Sigurd Knaub, PhD

Blood (2012) 120 (21): 4636.

https://doi.org/10.1182/blood.V120.21.4636.4636

Published: 2012

Journal Articles

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

Carmen Escuriola-Ettingshausen, MD, Vladimir Vdovin, MD, Nadezhda Zozulya, MD, PhD, Olga Plyushch, Prof, Wolfhart Kreuz, MD, Bruce A. Schwartz, PhD

Blood (2011) 118 (21): 3310.

https://doi.org/10.1182/blood.V118.21.3310.3310

Published: 2011

Journal Articles

ADAMTS13 Cleavage of Von Willebrand Factor (VWF) in Commercial Concentrates and Effect on VWF Function

Birte Fuchs, PhD, Barbera Solecka, PhD, Mario Kröning, Christoph Kannicht, PhD, Bruce A. Schwartz, PhD

Blood (2011) 118 (21): 4354.

https://doi.org/10.1182/blood.V118.21.4354.4354

Published: 2011

Journal Articles

Immune Tolerance Therapy in Children with FVIII Inhibitors

Vladimir Vdovin, MD, Pavel Svirin, MD, Ekaterina Shiller, MD, Bruce A. Schwartz, PhD

Blood (2011) 118 (21): 4656.

https://doi.org/10.1182/blood.V118.21.4656.4656

Published: 2011

Journal Articles

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Craig M. Kessler, MD, Bruce A. Schwartz, PhD, Oliver Hegener, Olaf Walter, MD, Sigurd Knaub, PhD

Blood (2010) 116 (21): 1424.

https://doi.org/10.1182/blood.V116.21.1424.1424

Published: 2010

Journal Articles

Relevance of Intact Von Willebrand Factor (VWF) Triplet Structure for VWF Function.

Bruce A. Schwartz, PhD, Birte Fuchs, PhD, Christoph Kannicht, PhD, Barbera Solecka, Mario Kröning

Blood (2010) 116 (21): 1425.

https://doi.org/10.1182/blood.V116.21.1425.1425

Published: 2010

Journal Articles

Comparison of Pharmacokinetic Properties of Two VWF/FVIII Concentrates In Subjects with Inherited Von Willebrand Disease (VWD)- Results of a Prospective, Randomized, Crossover Study.

Craig M. Kessler, MD, Jerry Powell, MD, Bruce A. Schwartz, PhD

Blood (2010) 116 (21): 3672.

https://doi.org/10.1182/blood.V116.21.3672.3672

Published: 2010

NARROW

Prospective, Phase III Study of the Efficacy, Safety, and Pharmacokinetics of a Human Antithrombin III Concentrate in Congenital Antithrombin Deficiency during Surgery or Childbirth

Efficacy and Safety of Human Fibrinogen Concentrate for the Treatment of Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials

Fiirst-2: Prospective, Randomized Study Comparing Administration of Clotting Factor Concentrates with Standard Massive Hemorrhage Protocol in Severely Bleeding Trauma Patients

Real-World Experience with a New Human Fibrinogen Concentrate (Fibryga®) in France for the Treatment of Bleeding Episodes and Surgical Prophylaxis

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Safety and Efficacy of Fibrinogen Concentrate in Congenital Fibrinogen Deficiency: A Post-Marketing Observational Study

Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency

Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency — a Phase 3 Study

Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency

Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates in Patients with Congenital Fibrinogen Deficiency: Final Analysis

Pharmacokinetic (PK) Comparison of Two Fibrinogen Concentrates for the Treatment of Congenital Fibrinogen Deficiency

Surgery in Von Willebrand Disease (VWD) Is Facilitated By a Novel 1:1 Plasma Derived Human Factor VWF/VIII Concentrate

Role of Von Willebrand Factor Triplet Bands in Glycoprotein Ib-Dependent Platelet Adhesion Under Flow Conditions

Treatment of Congenital Fibrinogen Deficiency; Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

ADAMTS13 Cleavage of Von Willebrand Factor (VWF) in Commercial Concentrates and Effect on VWF Function

Immune Tolerance Therapy in Children with FVIII Inhibitors

Assessing Haemostatic Efficacy In VWF/FVIII Replacement Therapy Trials Utilizing Subjective Vs. Objective Criteria – a Way to Improve Comparability and Accuracy of Clinical Outcome.

Relevance of Intact Von Willebrand Factor (VWF) Triplet Structure for VWF Function.

Comparison of Pharmacokinetic Properties of Two VWF/FVIII Concentrates In Subjects with Inherited Von Willebrand Disease (VWD)- Results of a Prospective, Randomized, Crossover Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only